Based on the successful launch of several cancer diagnostic image analysis tool s Visiopharm has initiated an Advisory Board focusing on providing strategic advice to the management with regards to this particular area.

We are very proud to have this particular expert panel to support our efforts in engaging with the medical and scientific community to develop products that are aimed at cancer diagnostic market needs.


Prof. Dr. Manuel Salto-Tellez

Professor Manuel Salto-Tellez (MD-LMS, FRCPath, FRCPI) is the Chair of Molecular Pathology at Queen’s University Belfast, Clinical Consultant Pathologist at the Belfast Health and Social Care Trust and Deputy Director of the Centre for Cancer Research and Cell Biology. By February 2016, Prof. Salto-Tellez was author or co-author of more than 210 internationally peer-reviewed articles in translational science, molecular pathology and diagnostics, including work published in NEJM, Nature Medicine, Gastroenterology, FASEB, EMBO, Cancer Research and Clinical Cancer Research, among others. He has published a similar number of abstracts in international conferences, and is editor or contributor to some of the key textbooks of pathology and oncology. Prof Salto-Tellez serves in a little more than 10 different committees amongst them UKNEQAS Committee for DNA Quality and as Chair of the Working Group on Pathology, Imaging and Diagnostics of Bowel Cancer UK. He is also in the editorial board in more than 4 esteemed journals.”

Prof. Dr.  Mogens  Vyberg

Professor  Mogens  Vyberg  graduated  with  MD  in  medicine  1973  and  was  board-certified  as  specialist  in  pathology 1984. Since 1988, he has been senior consultant at the Institute of Pathology, Aalborg University Hospital, and was appointed as professor of clinical pathology at Aalborg University in 2012. Prof.   Vyberg’s   main   clinical   expertise   and   research   fields   are   gastrointestinal,   liver   and   brain   pathology, immunohistochemistry and image analysis. He is author and co-author of about 130 peer reviewed scientific papers and   conference   abstracts,   and   several   book   chapters   in   these   fields.   He   is   head   of   the   Laboratory   for immunohistochemistry/R&D,  which  carries  out  quality  control  and  protocol  optimization  for  the  world’s  leading diagnostics companies. Prof.  Vyberg  is  also  co-founder  and  director  of  the  international  organization  Nordic  Immunohistochemical  Quality Control (NordiQC,, which was established in 2003 at the Institute of Pathology, Aalborg University Hospital, and currently serves more than 700 pathology laboratories from 85 countries. Prof.  Vyberg  is  board  member  of  the  International  Quality  Network  Pathology  and  the  International  Society  for Immunohistochemistry and Molecular Morphology.

Keith Miller, FIBMS, Scheme Director, UK NEQAS

Keith Miller, a Fellow of the Institute of Biomedical Sciences, has been employed at University College London as a medical scientist in pathology over several decades. He has been privileged to work with some outstanding academics, including Professor Peter Isaacson, who is associated with the discovery of Gastric MALT Lymphoma. Keith Miller's IHC laboratory played a pivotal role in providing the necessary evidence for this new entity. Keith Miller is a founding member and current Director of the UK National External Quality Assessment Scheme for Immunocytochemistry and In-situ Hybridisation. He has also developed the Advanced Diagnostics IHC and ISH clinical laboratory at UCL and this is now one of the largest testing centers of its kind in Europe today. Keith Miller has considerable experience with EQA in immunohistochemistry and related technology and has published extensively over the years. The pitfalls of setting up laboratory developed tests as companion diagnostics are well known to him. Keith Miller is continuously raising concerns about this issue as more and more targeted therapies are being released that require an IHC test as a companion diagnostic.


Assoc. Prof. Dr. Anne-Vibeke Lænkholm

Dr. Anne-Vibeke Lænkholm is an associate professor at the Department of Pathology, Zealand University Hospital, Denmark. Her main interest is diagnostic breast pathology and translational breast cancer research. In addition, she serves in a number of different committees amongst them as board member of The Danish Breast Cancer Cooperative Group (DBCG) and as member of the NordiQC HER-2 ISH Assessor Group and the EWGBSP. Associate prof. Anne-Vibeke Lænkholm is author or co-author of more than 45 peer reviewed articles.

Assoc. Prof. Dr. Johan Hartman

Johan Hartman is an associate professor of pathology at Karolinska University Laboratory, Stockholm, Sweden. His clinical interest is breast pathology. He is a PI at dept. of Oncology and Pathology, Karolinska Institutet and his research team is involved in both clinical and translational projects. His main research focus is cancer stem cells, cancer genomics/transcriptomics and image analysis for therapy prediction. Johan is heavily involved in the implementation of personalized cancer medicine at Karolinska. Associate prof. Johan Hartman is author or co-author of more than 35 peer reviewed articles, many in high-impact journals and with totally more than 2500 citations.